Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Improper mixing may cause unstable solutions with reduced biological effectiveness
But starting on a low dose of semaglutide and gradually increasing the dose over time can help reduce gastrointestinal side effects, including nausea
The powder form enables flexible formulation development, precise dosing control, and enhanced stability for pharmaceutical applications, making it an ideal API for next-generation diabetes drug development programs
Semaglutide for treating type 2 diabetes (TA689)
There was a slightly higher rate of gallbladder disorders in the semaglutide vs
US$ 27.34
US$ 29.84
US$ 20.64
US$ 22.32
US$ 21.86
US$ 21.38
US$ 21.76
US$ 22.17
US$ 22.57
